Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JANUX THERAPEUTICS, INC.

(JANX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
21.24(c) 21.51(c) 22.34(c) 25.02(c) 22.76(c) Last
79 784 65 079 30 200 76 022 76 533 Volume
+0.52% +1.27% +3.86% +12.00% -9.03% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1,11 M - -
Net income 2021 -23,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -23,0x
Yield 2021 -
Sales 2022 0,50 M - -
Net income 2022 -43,1 M - -
Net Debt 2022 - - -
P/E ratio 2022 -23,2x
Yield 2022 -
Capitalization 947 M 947 M -
Capi. / Sales 2021 856x
Capi. / Sales 2022 1 894x
Nbr of Employees 22
Free-Float 89,0%
More Financials
Company
Janux Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on its Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. Its focus is on developing a class of T cell engagers (TCEs). It is developing a broad pipeline with programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor... 
More about the company
All news about JANUX THERAPEUTICS, INC.
10/01JANUX THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direc..
AQ
09/20JANUX THERAPEUTICS, INC.(NASDAQGM : JANX) added to S&P TMI Index
CI
09/09JANUX THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/09JANUX THERAPEUTICS : Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors
BU
09/09Janux Therapeutics, Inc. Announces Board Appointments
CI
09/07JANUX THERAPEUTICS : to Present Virtually at the H.C. Wainwright 23rd Annual Global Invest..
BU
08/27JANUX THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direc..
AQ
08/10JANUX THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
08/10JANUX THERAPEUTICS : Successful $222.9 million IPO in June brings total funds raised in th..
PU
08/10JANUX THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
08/10JANUX THERAPEUTICS : Reports Second Quarter 2021 Financial Results
BU
08/10Janux Therapeutics, Inc. Reports Unaudited Earnings Results for the Second Quarter and ..
CI
07/19JANUX THERAPEUTICS : Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer
BU
07/19Janux Therapeutics Appoints Shahram Salek-Ardakani as Chief Scientific Officer of the C..
CI
07/16JANUX THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
More news
News in other languages on JANUX THERAPEUTICS, INC.

- No features available -

More news
Analyst Recommendations on JANUX THERAPEUTICS, INC.
More recommendations
Chart JANUX THERAPEUTICS, INC.
Duration : Period :
Janux Therapeutics, Inc. Technical Analysis Chart | JANX | US47103J1051 | MarketScreener
Technical analysis trends JANUX THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 22,76 $
Average target price 35,00 $
Spread / Average Target 53,8%
EPS Revisions
Managers and Directors
David Campbell President, Chief Executive Officer & Director
Tighe M. Reardon Chief Financial Officer
Jay B. Lichter Chairman
Shahram Salek-Ardakani Chief Scientific Officer
Wayne Godfrey Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
JANUX THERAPEUTICS, INC.0.00%947
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455